These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29369408)

  • 1. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach.
    Agrahari AK; Doss GPC; Siva R; Magesh R; Zayed H
    J Theor Biol; 2019 May; 469():163-171. PubMed ID: 30844370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries.
    Tomiyama H; Li Y; Funayama M; Hasegawa K; Yoshino H; Kubo S; Sato K; Hattori T; Lu CS; Inzelberg R; Djaldetti R; Melamed E; Amouri R; Gouider-Khouja N; Hentati F; Hatano Y; Wang M; Imamichi Y; Mizoguchi K; Miyajima H; Obata F; Toda T; Farrer MJ; Mizuno Y; Hattori N
    Mov Disord; 2006 Aug; 21(8):1102-8. PubMed ID: 16622854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.
    Park H; Kim T; Kim K; Jang A; Hong S
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical features of LRRK2-associated Parkinson's disease].
    Pchelina SN; Ivanova ON; Emel'ianov AK; Iakimovskiĭ AF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12):56-62. PubMed ID: 22433811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G2385R and I2020T Mutations Increase LRRK2 GTPase Activity.
    Ho DH; Jang J; Joe EH; Son I; Seo H; Seol W
    Biomed Res Int; 2016; 2016():7917128. PubMed ID: 27314038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain.
    Schmidt SH; Knape MJ; Boassa D; Mumdey N; Kornev AP; Ellisman MH; Taylor SS; Herberg FW
    Proc Natl Acad Sci U S A; 2019 Jul; 116(30):14979-14988. PubMed ID: 31292254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.
    Tan S; Gong X; Liu H; Yao X
    ACS Chem Neurosci; 2021 Sep; 12(17):3214-3224. PubMed ID: 34387082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of LRRK2 Inhibitors through Computational Drug Repurposing.
    Tan S; Lu R; Yao D; Wang J; Gao P; Xie G; Liu H; Yao X
    ACS Chem Neurosci; 2023 Feb; 14(3):481-493. PubMed ID: 36649061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.